ABCM

Abcam plc American Depositary Shares

ABCM

Market cap $5.52B

Delisted

ABCM was delisted on the 5th of December, 2023.

Back to rankings

About: Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.

Employees: 1,760

Healthcare Drug Manufacturers - General

Financial journalist opinion

Metabolism Assays Market Size Projected to Reach USD 3.1 Billion by 2034, Growing Steadily at 6.7% CAGR | Report by Transparency Market Research, Inc

Metabolism Assays Market Driven by Increase in Prevalence of Metabolic Disorders Metabolism Assays Market Driven by Increase in Prevalence of Metabolic Disorders

Metabolism Assays Market Size Projected to Reach USD 3.1 Billion by 2034, Growing Steadily at 6.7% CAGR | Report by Transparency Market Research, Inc

Danaher completes $5.7 billion acquisition of Abcam

Medical tools supplier Danaher said on Wednesday it has completed the $5.7 billion acquisition of Abcam , overcoming the initial opposition from the founder of the protein consumables maker.

Danaher Completes Acquisition of Abcam

WASHINGTON , Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the "Scheme") and the Scheme became effective in accordance with its terms on December 6, 2023.

Danaher Completes Acquisition of Abcam

Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam plc (Nasdaq: ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE: DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the ‘Scheme‘). The.

Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales

Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam today announced that all Identified Clearances required in connection with the acquisition of the company by Danaher have been obtained.

Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023

See News Rankings

Charts implemented using Lightweight Charts™